What you should know:
1. Omidria phenylephrine and ketorolac intraocular solution 1 percent/0.3 percent qualifies for separate payment retroactive to Oct. 1, 2020.
2. This is the first time Omidria is eligible under CMS’ payment policy for non-opioid pain management surgical drugs in the ASC.
3. Omidria is FDA-approved for use in cataract or lens replacement to prevent intraoperative pupil constriction and reduce postoperative ocular pain.
More articles on surgery centers:
10 recent ASC leadership moves
Virginia ASC takes infection prevention to new level — 3 insights
Surgery Partners goes all-in on cardiology — 5 quotes on its quarterly performance
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.